The group inoculated with rPRRSV-E2 produced PRRSV-specific immune effects. moderate interstitial pneumonia, lymph node congestion, and viremia. In contrast, the rPRRSV-E2 vaccination significantly alleviated the clinical signs, yielded Rabbit polyclonal to ACD a high level of antibodies, provided adequate protection against challenge with ZJqz21, and inhibited viral shedding and the viral load in target tissues. Our results demonstrated that the recombinant bivalent live vectored vaccine strain rPRRSV-E2 can provide efficient protection against the challenge of heterologous circulating NADC30-like strain and could be a promising vaccine candidate for the swine industry. and can be classified into PRRSV-1 and PRRSV-2 with Lelystad and VR-2332 as representative strains (Cavanagh, 1997; Lunney et al., 2016). These two genotypes share approximately 60% nucleotide identity (Darwich et al., 2011). PRRSV was first reported in 1996 in China. Over the past 20 years, PRRSV has been the cause of major diseases in the swine industry, and PRRSV-2 strains are highly predominant within the field (An et al., 2007). After 2006, highly pathogenic PRRSV (HP-RRRSV) became the predominantly epidemic strain on the farms (Tian et al., 2007, 2009; Zhou et al., 2008). Since 2013, PRRSV infection during routine clinical detection has significantly increased. The recurrent PRRS pandemic was attributed to the emergence NMS-859 of NADC30-like strains, which were likely imported from North NMS-859 America and rapidly spread widely throughout China (Zhao et al., 2015; Zhou et al., 2015; Li et al., 2017). The NADC30-like and HP-PRRSV-like strains currently circulate on pig farms and have high clinical detection rates (Li et al., 2016; Guo et al., 2019). According to the global PRRSV classification system, the abundance of PRRSV-2 strains in China can be classified into four lineages: NADC30-like (lineage 1), QYYZ-like (lineage 3), VR-2332-like (lineage 5), and JXA1-like/CH-1a-like (lineage 8) lineages (Shi et al., 2010a,b). Extensive genetic variations exist between the strains in each viral subtype, and genetically distinct PRRSV variants display different clinical characteristics and virulence (Guo et al., 2018). rPRRSV-E2 was a recombinant bivalent live vectored vaccine and capable of expressing the classical swine fever virus (CSFV) E2 protein in the backbone of a commercial modified live virus (MLV) vaccine strain, HuN4-F112, which was classified into lineage NMS-859 8 (Gao et al., 2018). rPRRSV-E2 could provide 100% protection against HP-PRRSV (lineage 8), but it remained to be answered about NMS-859 the protective effect of rPRRSV-E2 for resisting challenge with NADC30-like (lineage 1) strain. NADC30-like PRRSVs are not as pathogenic as HP-RRRSV but can be distinguished by a greater probability of recombination with other PRRSV strains, leading to NMS-859 different virulence (Zhang et al., 2016). Outbreaks of NADC30-like PRRSV in vaccinated swine herds indicate that the current commercial PRRSV vaccines cannot completely protect against infection with NADC30-like strains (Tian, 2017). This study evaluated the current vaccine candidate rPRRSV-E2 against infection with a heterologous strain and demonstrated that rPRRSV-E2 vaccination exerted superior efficiency at decreasing the clinical signs and viral infection NADC30-like strain in piglets. Materials and Methods Virus Isolation and Viral Characteristics Analyses The disease materials were obtained from a pig farm in Zhejiang province, China, in 2020. Three sick piglets displayed high fever, dyspnea, and tachypnea. Lung samples were ground and subjected to three freeze-thaw cycles in RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Waltham, MA). Samples were detected by PRRSV ORF5-specific primers, and the results appeared to be positive (data not shown). (PAMs) were infected with the supernatants for 1 h and subsequently cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS; Gibco). Daily observations were performed until obvious cytopathic effects (CPEs) appeared. Specific monoclonal antibodies termed SDOW17 (Rural Technologies) were used for an indirect immune fluorescent assay (IFA) to confirm the presence of the PRRSV N protein. Complete Genome Sequencing and Phylogenetic Analysis of ZJqz21 The total RNA was extracted from ZJqz21-infected PAMs using TRIzol (Invitrogen, Thermo Fisher Scientific, Waltham, MA). A PrimeScript? 1st Strand cDNA Synthesis Kit (TaKaRa, Dalian, China) was used for reverse transcription. The complete ZJqz21 genome was amplified by seven overlapping primers using the cDNA template. The sequences of all primers used.
The group inoculated with rPRRSV-E2 produced PRRSV-specific immune effects
- by globalhealth